ADAG
AdageneADAG
ADAG
About: Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Employees: 138
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
6.02% less ownership
Funds ownership: 18.92% [Q4 2024] → 12.9% (-6.02%) [Q1 2025]
13% less funds holding
Funds holding: 15 [Q4 2024] → 13 (-2) [Q1 2025]
43% less capital invested
Capital invested by funds: $20.3M [Q4 2024] → $11.6M (-$8.73M) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for ADAG.
Financial journalist opinion
Based on 3 articles about ADAG published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen
Neutral
GlobeNewsWire
2 weeks ago
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies' bispecific ADC development programs.
Neutral
GlobeNewsWire
3 weeks ago
Adagene announces up to $25 million strategic investment from Sanofi
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug
Neutral
GlobeNewsWire
2 months ago
Adagene to Present at Jefferies Global Healthcare Conference 2025
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place June 3-5 in New York, New York.
Neutral
GlobeNewsWire
2 months ago
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with
Neutral
GlobeNewsWire
3 months ago
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells.
Neutral
GlobeNewsWire
3 months ago
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.
Neutral
GlobeNewsWire
4 months ago
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses
Neutral
GlobeNewsWire
4 months ago
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.
Neutral
GlobeNewsWire
4 months ago
Adagene to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida.
Charts implemented using Lightweight Charts™